WebMar 9, 2024 · In the AEGEAN trial, the primary endpoints were pCR, defined as no viable tumor in the resection specimen (including lymph nodes) following neoadjuvant therapy, and EFS, defined as the time from randomization to an event like tumor recurrence, progression precluding definitive surgery, or death. WebJun 30, 2024 · Shots: The P-III (AEGEAN) trial evaluates the safety & tolerability of Imfinzi + neoadjucant CT vs CT alone in patients with NSCLC. The results from the combination therapy demonstrated a statistically significant improvement in pCR & MPR, consistent safety & tolerability, without a decrease in the number of patients to be able to undergo ...
Design and Rationale for a Phase III, Double-Blind, Placebo ... - PubMed
WebFeb 14, 2024 · In the context of NSCLC, a meta-analysis of 15 randomized-controlled trials found an OS benefit of 5% at 5 years with neoadjuvant chemotherapy compared to … WebMar 21, 2024 · Late-stage datasets already toplined and being presented in full at AACR include the Imbrave-050 study of Roche’s Tecentriq, the Aegean trial of Astra’s Imfinzi, and Keytruda’s Keynote-966 study. Given the failure of Merck’s anti-Tigit vibostolimab in Keyvibe-002, data from Keymaker-U02 substudy 02C, which contains vibostolimab, … sponge wand holder homemade
Nutritional Intervention-Clinical Trial Protocol
WebMar 10, 2024 · In the AEGEAN trial, the primary endpoints were pCR, defined as no viable tumour in the resection specimen (including lymph nodes) following neoadjuvant therapy, and EFS, defined as the time from randomisation to an event like tumour recurrence, progression precluding definitive surgery, or death. Key secondary endpoints were mPR, … WebJul 28, 2024 · An international expert consensus, authored by Duan et al. ( 1 ), saliently summarises the existing therapeutic options for patients with resected NSCLC and the key trials supporting them, as well as recommendations on patient evaluation, selection and monitoring. It alludes also to the areas of active research to further improve outcomes. WebJul 7, 2024 · The AEGEAN study is a randomized, double-blind trial that enrolled 802 patients. Patients were treated with a 1500 mg fixed-dose of durvalumab every 3 weeks … sponge wand refill